Association of Contrast Sensitivity With Eye Disease and Vision-Related Quality of Life.
Kathryn Flaharty, Leslie M Niziol, Maria A Woodward, Angela Elam, Amanda Bicket, Olivia J Killeen, Jason Zhang, Leroy Johnson, Martha Kershaw, Denise A John, Sarah K Wood, David C Musch, Paula Anne Newman-Casey
Summary
While CS alone is not sufficient to identify people with eye disease, it is an important measure of visual function that can add value to comprehensive eye screening.
Abstract
PURPOSE
To investigate contrast sensitivity (CS) as a screening tool to detect eye disease and assess its association with both eye disease and vision-related quality of life.
DESIGN
Cross-sectional study.
METHODS
Setting and population: Adults receiving care from a free clinic and a Federally Qualified Health Center in Michigan.
MAIN OUTCOME MEASURES
Screening positive for eye disease and Visual Function Questionnaire (VFQ) score.
OBSERVATION
Participants received a vision exam reviewed via telemedicine for disease, completed a demographic survey, and the 9-item VFQ. The ability of CS to predict eye disease was explored and area under the curve (AUC) is reported. Logistic and linear regression were used to investigate the continuous effect of CS on the probability of screening positive for eye disease and VFQ score, respectively, adjusting for age and visual acuity.
RESULTS
1159 included participants were, on average, 54.9 ± 14.5 years old, 62% identified as female, 34% as White, 54% as Black, 10% as Hispanic/Latino, and reported mean VFQ score of 79.7 ± 15.3. CS ranged from 0.00 to 1.95 log units (mean = 1.54 ± 0.24), 21% of eyes had glaucoma, 19% cataract, 6% DR, and 2% AMD. AUCs were 0.53 to 0.73. A 0.3 log unit decrease in better eye CS was associated with increased odds of glaucoma (odds ratio [OR] = 1.35, confidence interval [CI] = 1.09-1.67), cataract (OR = 1.35, CI = 1.05-1.72), DR (OR = 2.05, CI = 1.51-2.77), and AMD (OR = 2.08, CI = 1.10-3.91). A 0.3 log unit increase in better eye CS was associated with a 5.9 unit increase in VFQ.
CONCLUSION
While CS alone is not sufficient to identify people with eye disease, it is an important measure of visual function that can add value to comprehensive eye screening.
More by Kathryn Flaharty
View full profile →Engagement in the Michigan Screening and Intervention for Glaucoma and Eye Health through Telemedicine Program: Comparing the Effect of Clinic versus Community-Based Recruitment Strategies.
Qualitative Analysis of Barriers and Facilitators to Glaucoma Medication Adherence in a Randomized Controlled Trial Intervention.
Top Research in Quality of Life
Browse all →Neuroprotective strategies for retinal disease.
Detection and measurement of clinically meaningful visual field progression in clinical trials for glaucoma.
The Association Between Glaucoma, Anxiety, and Depression in a Large Population.
In the Knowledge Library
Discussion
Comments and discussion will appear here in a future update.